Collegium Pharmaceutical (COLL) vs Nuvectis Pharma (NVCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nuvectis Pharma (NVCT) has outperformed Collegium Pharmaceutical (COLL) over the past year, gaining 251.4% versus a loss of 33.3%. Collegium Pharmaceutical is the larger company by market cap ($719.2 million vs $689.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COLL | NVCT |
|---|---|---|
| Share price | $22.09 | $21.12 |
| Market cap | $719.15M | $689.44M |
| 1-day change | -0.09% | +4.92% |
| YTD return | -52.25% | +179.74% |
| 1-year return | -33.26% | +251.41% |
| 5-year return | +5.39% | — |
| P/E ratio (TTM) | 17.39 | — |
| Forward P/E | 3.33 | — |
| EPS (TTM) | $1.27 | $-1.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $50.79 | $29.28 |
| 52-week low | $21.43 | $5.55 |
| Distance from 52-week high | -56.50% | -27.86% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +121.82% | +67.61% |
| Average volume | 749.33K | 215.43K |
| Shares outstanding | 32.56M | 32.64M |
| Employees | 423 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCT has outperformed COLL by 284.7 percentage points over the past year.
About Collegium Pharmaceutical
COLL stock →Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
COLL vs NVCT FAQ
Which is bigger, Collegium Pharmaceutical or Nuvectis Pharma?
Collegium Pharmaceutical (COLL) is larger, with a market capitalization of $719.15M compared with $689.44M for Nuvectis Pharma (NVCT).
Which stock has performed better over the past year, COLL or NVCT?
NVCT returned +251.41% over the past 12 months, compared with -33.26% for COLL (price return, excluding dividends). Past performance does not predict future results.
Are Collegium Pharmaceutical and Nuvectis Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.